hyundai motor manufacturing czech s.r.o.

What hyundai motor manufacturing czech s.r.o. does

Cayman Pharma s.r.o. is a privately held Czech pharmaceutical manufacturer specializing in cGMP production of prostaglandin-based active pharmaceutical ingredients (APIs). The company traces its origins to 1978, when prostaglandin development was initiated at Spolana in collaboration with the Chemical Institute of Technology in Prague; it was acquired in 2006 by Cayman Chemical (USA) from its predecessor entity NeraPharm, of which it remains a wholly-owned subsidiary. Headquartered in Neratovice, Czech Republic with approximately 120 scientists and manufacturing specialists, Cayman Pharma serves pharmaceutical customers in more than 50 countries and operates within a regulatory framework covering EMA, FDA, SUKL, USKVBL, ANVISA, PMDA, and a CEP for Latanoprost.

The company's product portfolio is organized across three therapeutic categories: ophthalmology APIs (Latanoprost, Bimatoprost, Tafluprost, Travoprost, Latanoprostene Bunod for glaucoma and ocular hypertension), animal health APIs (Cloprostenol variants for veterinary reproductive management), and vascular APIs (Epoprostenol sodium for pulmonary hypertension). Manufacturing is supported by specialized technical capabilities including OEB 4/5 high-containment production, 20+ step multi-step synthesis, cryogenic reaction handling from -70°C to +100°C, high-pressure hydrogenation, and enantioselective separations — combined under cGMP with dedicated human and veterinary cleanroom capacity. In 2025, the company launched CDMO (Contract Development and Manufacturing Organization) services, extending its platform to custom API route design, process development, and contract manufacturing for external pharmaceutical clients.

Cayman Pharma operates an enterprise B2B go-to-market combining direct field sales with engagement at major industry events (CPHI, DCAT Week, CHEMSPEC Europe, CDMO Live) and structured website inquiry forms (API Inquiry, CDMO Partnership, Research Collaboration, Technical Documentation). Revenue is generated through proprietary API product sales to global pharma customers and, since 2025, through professional CDMO service contracts. Pricing is not publicly disclosed; quotes are provided on request. The customer base spans pharmaceutical companies requiring technically demanding APIs for clinical and commercial supply across human and veterinary indications.

Name

hyundai motor manufacturing czech s.r.o.

Legal name

Cayman Pharma s.r.o.

Website

https://caymanpharma.cz

Company type

Private

Founded year

1978

Operating status

Operating

Short description

Cayman Pharma s.r.o. is a Czech-based cGMP manufacturer of prostaglandin active pharmaceutical ingredients for ophthalmology, vascular, and animal health indications, serving global pharmaceutical customers across 50+ countries with approximately 120 employees.

Ownership category

akta.pro rank

Product category

Active Pharmaceutical Ingredient Manufacturing

NAICS

Pharmaceutical and Medicine Manufacturing (3254)

SIC

Medicinal Chemicals & Botanical Products (2833)

akta.pro industry

PRIMARYHLAGAHAB

Small-Molecule API Commercial Manufacturing

Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/API & Small-Molecule Development/Manufacturing Services

SECONDARYHLAGAHAM

Small-Molecule CMC Documentation & Regulatory Support (DMF/CMC)

Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/API & Small-Molecule Development/Manufacturing Services

SECONDARYHLAIABAG

Generic APIs & Intermediates (Active Ingredients)

Healthcare & Life Sciences/Pharmaceuticals/Generic Pharmaceuticals

SECONDARYHLAIAAAL

Ophthalmology Pharmaceuticals

Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals

Keywords

• Active pharmaceutical ingredients
• Prostaglandin APIs
• Contract manufacturing services
• High-potency API manufacturing
• CGMP pharmaceutical synthesis

Headquarters

HQ city

Neratovice

HQ country

Czechia

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Supply Chain, Infrastructure, Technology or R&D, Marketing or Sales

Revenue model

1. API Manufacturing and Sales: Cayman Pharma manufactures and sells Active Pharmaceutical Ingredients (APIs), particularly prostaglandins for ophthalmology, animal health, and vascular applications. Products include Latanoprost, Bimatoprost, Latanoprostene Bunod, Tafluprost, Travoprost, Epoprostenol sodium, and Cloprostenol variants. GMP material is sold to pharmaceutical companies worldwide.
2. CDMO Contract Services: Contract Development and Manufacturing Organization services including technology transfer, process optimization, process validation, and commercial process verification. Services span from early route design through clinical supply and commercial manufacturing for technically demanding APIs.
3. Contract Research Services: CRO and CDMO services including bioanalysis and assay development, medicinal chemistry and structural biology, analytical chemistry, and chemical synthesis services.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

Cayman Pharma manufactures and sells prostaglandin-based active pharmaceutical ingredients (APIs) under cGMP for ophthalmology, animal health, and vascular/pulmonary hypertension therapies. The company complements its API manufacturing with Contract Development and Manufacturing Organization (CDMO) services and contract research services spanning bioanalysis, medicinal chemistry, analytical chemistry, and chemical synthesis for pharmaceutical clients worldwide.

Product overview

Cayman Pharma operates as a GMP-certified manufacturer of active pharmaceutical ingredients specializing in prostaglandin-based APIs. The company offers a portfolio organized across three therapeutic categories: Ophthalmology APIs (Latanoprost, Bimatoprost, Tafluprost, Travoprost, Latanoprostene Bunod for glaucoma treatment), Animal Health APIs (Cloprostenol variants for veterinary reproduction), and Vascular APIs (Epoprostenol for pulmonary hypertension). These products are supported by cGMP manufacturing capabilities and complemented by Contract Development and Manufacturing Organization (CDMO) services for custom API development, as well as global API contract services spanning bioanalysis, medicinal chemistry, analytical chemistry, and chemical synthesis.

Differentiator

Problem solved

Functional benefit

Products and services

• Ophthalmology APIs Advanced prostaglandin analogue APIs for management of glaucoma and ocular hypertension, including Latanoprost, Bimatoprost, Tafluprost, Travoprost, and Latanoprostene Bunod, supplied as cGMP material to pharmaceutical companies for human ophthalmic drug formulations.
• Animal Health APIs Specialized prostaglandin APIs for veterinary medicine, including Cloprostenol sodium salt variants and Cloprostenol Free Acid used for reproductive management in domestic mammals.
• Vascular APIs Advanced prostaglandin analogues for vascular and pulmonary hypertension therapies, including Epoprostenol sodium salt, supplied as cGMP material for human medicine.
• CDMO Services Contract Development and Manufacturing Organization services for complex custom APIs, supporting pharmaceutical companies from early route design through clinical supply and commercial manufacturing, including technology transfer, process optimization, process validation, and commercial process verification.
• API Manufacturing cGMP manufacturing of active pharmaceutical ingredients for clients worldwide for use in human and veterinary medicine, leveraging over 50 years of synthesis experience in prostaglandins and complex multi-step synthesis.
• Global Contract Research Services CRO-style API contract services including bioanalysis and assay development, medicinal chemistry and structural biology, analytical chemistry, and chemical synthesis services for pharmaceutical partners.

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature7 records

Partnerships

One partnership is on record.

• Cayman Chemical (USA)coreOthers · 1 January 2006Cayman Pharma is a proud subsidiary of Cayman Chemical (USA), a GMP-certified manufacturer of active pharmaceutical ingredients. Cayman Chemical acquired NeraPharm in 2006, rebranding it to Cayman Pharma. The merger united transatlantic research excellence with European manufacturing mastery.

Scale indicators3 records

Recent moves10 records

Expansion highlights5 records

Others

• Cayman Chemical: Parent company of Cayman Pharma. Cayman Chemical is a US-based GMP manufacturer of APIs and biochemical research reagents; the two organizations share prostaglandin chemistry know-how and have a documented history of technology transfer (e.g., Bimatoprost). Comparable because of overlapping API manufacturing capabilities and pipeline linkage, though Cayman Chemical also serves the research reagents market that Cayman Pharma does not.

Direct peers

• Hovione: Portugal-based CDMO specializing in complex small-molecule APIs, including high-potency and corticosteroid APIs, with strong particle engineering and GMP manufacturing. Directly comparable to Cayman Pharma in targeting technically demanding, lower-volume custom API programs requiring sophisticated chemistry and containment.
• Chirogate International: Taiwanese specialty API manufacturer focused specifically on prostaglandin chemistry, with capabilities analogous to Cayman Pharma in ophthalmology and veterinary prostaglandin APIs. Closest single-product competitor in the prostaglandin niche Cayman Pharma dominates.
• EUROAPI: European API manufacturer spun out of Sanofi, producing both branded and generic APIs across multiple therapeutic areas with cGMP capabilities. Comparable to Cayman Pharma in API manufacturing model, regulatory certification footprint, and focus on complex small molecules, though operating at much larger scale and broader therapeutic scope.
• Olon Group: Italian CDMO and generic API manufacturer with cGMP facilities across fermentation and chemical synthesis. Comparable to Cayman Pharma as a mid-sized European API manufacturer pursuing complex generic and CDMO APIs with multi-jurisdictional GMP approvals.
• AGC Pharma Chemicals (CMO): European CDMO focused on custom small-molecule API development and manufacturing, with particular strength in high-potency and complex synthesis. Comparable to Cayman Pharma's CDMO positioning and target client base of pharma companies needing technically demanding custom APIs.
• Fermion (Orion Corporation): Finnish API manufacturer (subsidiary of Orion) focused on generic and contract-manufactured small-molecule APIs with strong high-potency capabilities. Comparable to Cayman Pharma as a European mid-sized API manufacturer pursuing complex generics and custom CDMO work.

Broad incumbents

• Cambrex (Thermo Fisher Pharma Services): Large US/EU CDMO offering small-molecule API development and manufacturing across multiple sites. Comparable to Cayman Pharma's CDMO/API business model, but Cambrex operates at significantly larger scale and broader modality coverage, making it a relevant competitive benchmark rather than a direct specialty competitor.
• Lonza Small Molecules: Global CDMO leader with extensive small-molecule API manufacturing capacity, including high-containment capabilities. Comparable as an incumbent CDMO competing for custom API programs, though Lonza's scale and modality breadth dwarf Cayman Pharma's specialty footprint.
• WuXi STA (STA Pharmaceutical): Large Asia-based CDMO providing end-to-end small-molecule API development and manufacturing services. Comparable in CDMO service offering and target pharma client base, but operates at vastly larger scale with broader therapeutic and modality coverage.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

• Facebookfacebook.com/CaymanPharma
• LinkedInlinkedin.com/company/cayman-pharma-s-r-o-

Compliance10 records

Revenue estimate

Valuation estimate

Number of profiles

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about hyundai motor manufacturing czech s.r.o.